DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $642 | -26.6% | 31,102 | +4.8% | 0.00% | -33.3% |
| Q2 2023 | $875 | +29.6% | 29,665 | +1.3% | 0.01% | +20.0% |
| Q1 2023 | $675 | -7.2% | 29,287 | +12.0% | 0.01% | 0.0% |
| Q4 2022 | $727 | -99.9% | 26,149 | -7.3% | 0.01% | -16.7% |
| Q3 2022 | $866,000 | +112.3% | 28,221 | +103.3% | 0.01% | +100.0% |
| Q2 2022 | $408,000 | -23.0% | 13,879 | -15.8% | 0.00% | 0.0% |
| Q1 2022 | $530,000 | -23.6% | 16,488 | +5.9% | 0.00% | 0.0% |
| Q4 2021 | $694,000 | +9.5% | 15,569 | +23.8% | 0.00% | 0.0% |
| Q3 2021 | $634,000 | -21.2% | 12,573 | +22.6% | 0.00% | -25.0% |
| Q2 2021 | $805,000 | +61.3% | 10,259 | +17.5% | 0.00% | +33.3% |
| Q1 2021 | $499,000 | -17.4% | 8,733 | +21.0% | 0.00% | -25.0% |
| Q4 2020 | $604,000 | – | 7,216 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,705,039 | $343,645,000 | 25.68% |
| Casdin Capital, LLC | 1,500,000 | $66,900,000 | 1.89% |
| Flagship Pioneering Inc. | 2,619,968 | $116,851,000 | 1.81% |
| SECTORAL ASSET MANAGEMENT INC | 189,600 | $8,456,000 | 1.27% |
| Integral Health Asset Management, LLC | 100,000 | $4,460,000 | 1.23% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $239,479,000 | 0.86% |
| Goldstream Capital Management Ltd | 78,418 | $3,497,000 | 0.86% |
| Yiheng Capital Management, L.P. | 335,184 | $14,949,000 | 0.76% |
| GILDER GAGNON HOWE & CO LLC | 2,900,114 | $129,345,000 | 0.74% |
| Artal Group S.A. | 600,000 | $26,760,000 | 0.73% |